Stock Taper
SCREENER COMPARE ANY 2 STOCKS
INTS
INTENSITY THERAPEUTICS, INC.
NASDAQ
$4.25
▼ DOWN 0.47% (-0.02)

KEY STATISTICS

Market Cap$11.49 M
52w High$43.50
52w Low$3.51
Dividend Yield—
Frequency—
P/E-1.50
Volume22.42K
Shares Out.2.70M

COMPANY

LEADERSHIP

Lewis H. Bender
CHIEF EXECUTIVE
Lewis H. Bender

COMPENSATION 2026

Salary$549,150
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$54,331
Total$1,355,482

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 30, 2023
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
16

PRICE TARGET

Target High$15.00
Target Low$7.00
Target Median$11.00
Target Consensus$11.00

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.—
NOV
5
THU

SPLIT RECORD

DATETYPERATIO
2026-02-19Reverse1:25

PRICE

$4.25 ▼ DOWN 0.47% (−$0.02)
OVERLAYS
$4.20$4.35$4.509:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM4.25

About Intensity Therapeutics, Inc.

https://www.intensitytherapeutics.com ↗

Intensity Therapeutics, Inc. is a clinical-stage biotech developing cancer drugs like INT230-6 for solid tumors, with collaborations involving Merck, Bristol-Myers, and research institutes.

INDUSTRY

Biotechnology

A PRODUCT INTENSITY THERAPEUTICS, INC. IS KNOWN FOR

INT230-6
INT230-6

INT230-6 is a clinical-stage intratumoral cancer drug combining cisplatin and vinblastine sulfate via Intensity Therapeutics' DfuseRx℠ platform to directly kill tumors and stimulate systemic immune responses.

ETFS HOLDING THIS STOCK

ETFS HOLDING
1
LISTED HERE
1
RANKED BY POSITION SIZE
VXF
0.00% · 26.6K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
38
TOP 12 OF 38 · RANKED BY POSITION SIZE
Sapient Capital LLC
976.8K sh · $239.71K
Vanguard Group Inc
649.1K sh · $266.13K
Sentinus, LLC
495.9K sh · $203.42K
Geode Capital Management, LLC
460.2K sh · $188.79K
Mesirow Financial Investment Management, Inc.
251.0K sh · $102.96K
Legacy Advisors, LLC
153.4K sh · $62.94K
Creative Planning
143.1K sh · $58.71K
Ubs Group AG
136.2K sh · $33.1K
State Street Corp
136.2K sh · $55.87K
Brown Advisory Inc
130.1K sh · $31.57K
Ci Private Wealth, LLC
100.0K sh · $41.02K
Stonebridge Financial Group, LLC
77.4K sh · $31.74K

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR
DUBIN THOMAS I H
Purchase · 5.5K shares
2026-07-16
★
DIRECTOR
Donovan Daniel
Purchase · 5.5K shares
2026-07-16
★
DIRECTOR
GOLDBERG MARK A
Purchase · 5.5K shares
2026-07-16
★
DIRECTOR
Leahy Emer
Purchase · 5.5K shares
2026-07-16

SECTORS PEERS

PEERPRICE
QTTB$15.03COMPARE
ANTX$5.58COMPARE
RLYB$16.81COMPARE
BOLD$2.83COMPARE
NXTC$6.09COMPARE
IBIO$1.36COMPARE
PLUR$1.53COMPARE